Cardiac Monitoring Devices Market Size & Share 2026-2035

Cardiac Monitoring Devices Market Size

The cardiac monitoring devices market was valued at USD 15 billion in 2025 and is projected to increase from USD 16 billion in 2026 to USD 29 billion by 2035, expanding at a 6.8% CAGR. This trajectory reflects a care-delivery shift toward detecting episodic and asymptomatic rhythm abnormalities outside short clinical encounters.

Clinical demand is anchored in cardiovascular disease burden. Cardiovascular diseases caused an estimated 19.8 million deaths in 2022, or about 32% of global deaths, while heart attack and stroke accounted for 85% of those deaths. ^{[1]World Health Organization, Cardiovascular diseases (CVDs) fact sheet, updated 2024, who.int} Global cardiovascular disease prevalence reached 626 million cases in 2023, compared with 311 million in 1990. ^{[2]Journal of the American College of Cardiology, Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023, 2025, jacc.org} Atrial fibrillation, a principal indication for prolonged rhythm surveillance, affected 52.55 million people in 2021, up from 22.21 million in 1990.

Population aging makes that demand durable. The number of people aged 60 years or older is expected to reach 1.4 billion by 2030, from 1 billion in 2020. As the pool of patients with hypertension, diabetes, ischemic disease, and age-related conduction disorders expands, the clinical limitation of a single resting ECG becomes more consequential. Monitoring duration, signal quality, and the ability to route clinically meaningful events into physician workflows are therefore becoming more important purchase criteria.

The adoption constraint is operational rather than purely technical. Long-duration patches, mobile telemetry, and insertable monitors generate more data than episodic testing, making alert precision and remote workflow integration central to adoption. Suppliers that lower false-alert burden while preserving clinically relevant episodes can make longer monitoring periods viable for cardiology practices and health systems, rather than merely adding another device to the diagnostic pathway.

Key Drivers

Rising Aging Population and Increased Risk of Cardiovascular Diseases

Aging increases both the incidence of rhythm disorders and the clinical value of monitoring outside acute episodes. The population aged 65 years and older is projected to rise from 770.4 million in 2022 to 1.58 billion by 2050. This supports demand across standard ECG, Holter, telemetry, patch, and insertable-monitor pathways, although the mix shifts toward longer-duration modalities when symptoms are infrequent or absent.

Atrial fibrillation is especially relevant because it can be intermittent and is associated with stroke risk. Its prevalence among people aged 65 years and older reached about 38.96 million in 2021. The resulting diagnostic need extends beyond hospitals: a monitoring pathway may begin with an outpatient ECG but require an ambulatory patch, telemetry service, or insertable monitor before a clinician can establish rhythm burden.

Lifestyle Changes and Increasing Prevalence of Heart Diseases

Modifiable risk factors accounted for an estimated 79.6% of the global cardiovascular disease burden in 2023. Hypertension, obesity, diabetes, tobacco exposure, and inactivity widen the target population for cardiac assessment beyond the oldest age groups. For suppliers, this expands demand in diagnostic centers and outpatient practices, but it also heightens the need for lower-cost devices and simpler clinical workflows in markets where advanced remote-monitoring reimbursement is limited.

The commercial effect differs by care setting. Acute and high-risk patients support demand for telemetry and continuous monitoring, whereas primary-care and prevention pathways favor accessible ECG systems and wearable screening tools. This creates room for both established diagnostic platforms and digitally connected devices, but it does not make them interchangeable: the appropriate modality depends on symptom frequency, clinical acuity, and the availability of downstream interpretation.

Advancements in Remote Monitoring and Wearable Technology

Extended-wear systems move rhythm capture into normal daily activity, improving the likelihood of recording episodic events. iRhythm launched its Zio ECG Recording and Analysis System in Japan in May 2025, offering an AI-powered long-term continuous monitoring service with up to 14 days of recording. ^{[3]iRhythm Technologies, iRhythm Launches Zio Long-Term Continuous Monitoring Service in Japan as the Zio ECG Recording and Analysis System, 2025, investors.irhythmtech.com} Such platforms alter the service model as well as the hardware requirement: providers need ordering, patient onboarding, analysis, report delivery, and escalation processes that function outside the hospital.

Interoperability is becoming a practical constraint on that model. The American Heart Association has identified data interoperability, security, and governance as material issues for ambulatory cardiovascular monitoring. Connected-monitoring suppliers consequently compete on integration with clinical systems and the quality of their data-management architecture, rather than on electrode and recorder design alone.

Advancements in Digital Health and AI

Artificial intelligence is increasingly deployed to classify rhythm events before clinician review. A 2025 study of AI-assisted direct-to-physician ambulatory ECG reporting reported 98.6% sensitivity for critical arrhythmias, compared with 80.3% for trained ECG technicians in the evaluated workflow. The commercial relevance lies in triage: reducing the volume of low-value alerts can support wider use of longer monitoring periods without requiring a proportional increase in technician capacity. ^{[4]Nature Medicine, Artificial intelligence for direct-to-physician reporting of ambulatory electrocardiography, 2025, nature.com}

Handheld and consumer-facing ECG systems are also extending the entry point into cardiac assessment. AliveCor received FDA clearance in June 2024 for its Kardia 12L ECG System and KAI 12L AI technology, which together support 35 cardiac determinations. These tools do not eliminate the need for physician interpretation or clinical confirmation, but they can bring diagnostic-quality ECG acquisition closer to primary, urgent, and distributed-care settings.

Key Restraints

Data Privacy and Security Concerns

Remote cardiac monitoring handles sensitive rhythm, symptom, and physiological data across patient devices, connectivity layers, cloud platforms, and clinical workstations. The GDPR imposes requirements concerning lawful processing, purpose limitation, data minimization, and safeguards for health data. These requirements affect product design, vendor contracting, cybersecurity controls, and the pace at which providers can deploy connected-monitoring workflows across European markets.

U.S. consumer-facing health applications have also faced a tighter privacy environment. The FTC's amended Health Breach Notification Rule took effect on July 29, 2024, broadening notification obligations for certain health applications and connected devices that are not covered by HIPAA. For cardiac-monitoring vendors, governance capability has therefore become part of market access and institutional procurement, especially where systems exchange data with hospitals or remote monitoring services.

High Cost of Advanced Monitoring Solutions

Insertable cardiac monitors, mobile cardiac telemetry, and AI-enabled extended-wear patches involve more than device acquisition. They can require implantation, connectivity, clinical review, service infrastructure, and ongoing data-management capacity. Where reimbursement supports these pathways, the higher initial expenditure can be justified by diagnostic yield and reduced repeat testing. Where coverage is fragmented, procurement tends to remain concentrated in tertiary facilities or shift toward conventional ECG and Holter equipment.

This distinction is most consequential in price-sensitive health systems. Demand may be clinically strong while the addressable market for premium continuous-monitoring systems remains narrow. Manufacturers that can pair reliable core diagnostics with scalable analysis and service models are better placed to participate in emerging-market demand than suppliers relying solely on high-cost implanted or continuous-telemetry offerings.

The market will therefore fragment by workflow maturity. Health systems with reimbursement, specialist capacity, and interoperable digital infrastructure can adopt telemetry, patches, and insertable monitors more quickly. In other settings, conventional ECG and Holter systems remain commercially important because they offer a lower-cost route to basic rhythm assessment. This divergence favors portfolios that span care acuity and price points rather than a single premium modality.

Cardiac Monitoring Devices Market Segment Analysis

By Device Type

ECG monitors hold 34.5% of the 2025 market because resting and continuous ECG remain foundational tools for initial rhythm and ischemia assessment. Their installed base in hospitals, emergency departments, cardiology clinics, and primary-care settings creates recurring replacement and software-upgrade demand. GE HealthCare's cardiology portfolio illustrates the value of linking ECG acquisition, automated analysis, and information-system workflows rather than treating the recorder as a standalone product.

Holter monitors account for 16.5% of the 2025 market. They retain a role where multi-channel recordings, established clinical pathways, and cost discipline matter, although longer-wear patches and telemetry systems increasingly compete for ambulatory use cases. Schiller's medilog portfolio demonstrates how Holter suppliers are extending recording duration and analytical capability to preserve relevance in this segment.

Event recorders and external loop recorders represent 6.7% of the market. Their patient-triggered design is suited to infrequent symptomatic episodes, but the modality is structurally disadvantaged when symptoms are absent or when continuous capture is clinically required. As a result, it ranks fifth by CAGR among device types.

Mobile cardiac telemetry devices account for 15.6% of the 2025 market and rank second by CAGR. Their value rests on continuous transmission and time-sensitive escalation rather than simply longer recording. The segment benefits where clinicians and service providers can staff or automate the review process, making it more dependent on reimbursement and operational infrastructure than basic Holter monitoring.

Implantable cardiac monitors account for 15.2% of the market and are the fastest-growing device type. The category addresses diagnostic questions that require surveillance over months or years, including unexplained syncope, cryptogenic stroke evaluation, and covert atrial fibrillation detection. Medtronic reported that its AccuRhythm AI update for Reveal LINQ targeted an 85% cumulative reduction in false atrial fibrillation and pause alerts while preserving high true-alert sensitivity. BIOTRONIK reported that BIOMONITOR IV's SmartECG algorithm reduced false detections while retaining clinically relevant episodes. These developments address an adoption bottleneck by making long-term monitoring more manageable for clinical teams.

Other device types, including patch-based monitors and related wearable systems, hold 11.5% share. Their appeal lies in an intermediate position between brief Holter studies and real-time telemetry: extended capture can be achieved with less patient burden than wired systems, while analysis can remain centralized after wear completion.

By Type

Non-wearable devices account for 52% of the 2025 market. Hospital ECG workstations, bedside telemetry, stationary diagnostic systems, and implantable monitors sustain this majority through capital equipment requirements and clinically supervised use cases.

Wearable devices account for 48% and are the fastest-growing type segment, projected to reach USD 14.2 billion by 2035. Their growth is tied to convenience, longer recording windows, and a care model that captures rhythm data during ordinary activity. The segment's expansion does not imply a uniform shift to consumer devices; physician-prescribed patches and clinically integrated wearables remain important where diagnostic reports must feed formal treatment decisions.

By Application

Arrhythmia detection holds 56.58% of the 2025 market. Atrial fibrillation represents 65.1% of this application, followed by tachycardia at 18.8%, bradycardia at 9.2%, and PACs/PVCs at 6.9%. The prominence of atrial fibrillation reflects both its prevalence and the mismatch between intermittent disease expression and brief clinical tests.

Cardiac ischemia and myocardial infarction detection account for 19.0% of the market. Here, monitoring supports acute-care triage and continuous surveillance for ischemic changes, placing more weight on signal fidelity and timely clinical response than on patient wear time.

Heart rate and rhythm monitoring accounts for 8.0% and is the fastest-growing application. Broader use of connected wearables and remote monitoring supports chronic-disease follow-up and post-discharge observation, but the application's growth depends on how effectively providers distinguish clinically actionable findings from high-volume routine data.

Syncope and palpitation monitoring represents 9.67% of the market and ranks second by CAGR. Because causative rhythm disturbances may be infrequent, diagnostic yield rises with monitoring duration. Pre/post-operative monitoring accounts for 4.33%, supported by surveillance around cardiac procedures and high-acuity episodes. Other applications account for 2.42%.

By End Use

Hospitals hold 42.9% of the market, or USD 6.4 billion in 2025. They remain the central setting for acute diagnosis, intensive monitoring, perioperative care, and device implantation. Their fourth-place CAGR reflects a mature installed base rather than reduced clinical importance.

Diagnostic centers account for 24.6% and provide a lower-cost outpatient venue for Holter analysis, ambulatory ECG studies, and related cardiac assessments. Ambulatory surgery centers hold 17.1% and rank second by CAGR as selected cardiac procedures migrate toward lower-cost procedural settings.

Homecare settings account for 11.3% and are the fastest-growing end-use segment. Growth reflects the widening availability of remote monitoring workflows and patient-worn devices, but sustainable adoption requires dependable connectivity, physician oversight, and reimbursement that recognizes the review burden. Other end users account for 4.1%.

The same logic explains why wearable devices and homecare settings are growing faster than the established non-wearable and hospital bases. The shift is not simply from clinical to consumer care; it is from location-bound testing to clinically governed data capture in daily life. Suppliers that can combine patient adherence, analytical accuracy, and efficient clinical reporting will have an advantage over vendors competing on device form factor alone.

Cardiac Monitoring Devices Market Regional Analysis

North America

North America holds the largest market share in 2025. The U.S. market reached USD 5.6 billion in 2025, from USD 5.2 billion in 2024. The region's scale reflects specialist infrastructure, broad use of ambulatory monitoring, and a reimbursement environment capable of supporting advanced diagnostic pathways. Heart disease remains a leading U.S. cause of death, and approximately 805,000 people experience a heart attack each year. ^{[5]Centers for Disease Control and Prevention, Heart Disease Facts & Statistics, cdc.gov} Canada contributes through hospital-based ECG, Holter, and ambulatory monitoring adoption.

Europe

Europe accounts for USD 4.2 billion in 2025. Germany, the UK, France, Spain, Italy, and the Netherlands support demand through established cardiology services and hospital networks, while the EU regulatory and privacy environment raises the importance of compliance-ready connected platforms. Philips reported a UK pilot at University Hospitals Sussex using ePatch monitoring and Cardiologs AI analysis for two-week ambulatory ECG studies. ^{[6]Philips, First NHS Heart Patients Monitored with Philips Wearable ePatch and AI ECG Analysis Platform Cardiologs, 2024, philips.co.uk} Such deployments demonstrate the region's interest in replacing short, wired studies with digitally supported extended monitoring, but implementation remains tied to local procurement and data-governance requirements.

Asia Pacific

Asia Pacific is the fastest-growing region, at an approximately 7.5% CAGR. China, Japan, India, Australia, and South Korea combine large patient populations with uneven access to advanced cardiac diagnostics. Japan offers a particularly favorable setting for long-duration monitoring because of population aging and mature clinical infrastructure. iRhythm's May 2025 launch of the Zio service in Japan illustrates increasing availability of extended ambulatory monitoring in the region.

China and India create a different market configuration. Urban tertiary centers can adopt advanced systems, while broad-based expansion depends on affordable ECG, Holter, and wearable offerings that can operate across varied provider settings. Australia and South Korea support uptake of digitally connected monitoring through comparatively mature healthcare and technology ecosystems.

Latin America

Brazil, Mexico, and Argentina represent a developing opportunity shaped by cardiovascular disease burden and aging, but constrained by reimbursement fragmentation, import dependence, and public-procurement budgets. Standard ECG and Holter equipment are likely to remain the primary entry point in many settings, while advanced telemetry and implanted systems concentrate in private and tertiary-care channels.

Middle East and Africa

South Africa, Saudi Arabia, and the UAE anchor regional demand. Saudi Arabia and the UAE offer stronger near-term potential for advanced monitoring where hospital investment and digital-health programs support specialty cardiac care. South Africa provides an important entry market in sub-Saharan Africa, though budget limitations constrain the diffusion of premium continuous-monitoring solutions beyond private hospitals and major urban facilities.

Asia Pacific's approximately 7.5% CAGR reflects a larger expansion runway, but the opportunity is bifurcated. Japan can support sophisticated long-term monitoring services, as the Zio launch indicates, whereas China and India require a broader mix of affordable diagnostic equipment, localized service capacity, and scalable digital tools. Manufacturers that impose one high-cost product architecture across these markets risk missing the volume opportunity created by underdiagnosis and uneven access.

Cardiac Monitoring Devices Market Share & Competitive Landscape

Competition spans diversified medtech companies with hospital-monitoring infrastructure and specialized providers focused on ambulatory, insertable, or personal ECG modalities. Product success increasingly depends on the surrounding workflow: data transmission, algorithmic event classification, reporting, clinician review, and integration with healthcare information systems.

Medtronic

Medtronic competes in insertable cardiac monitoring through the Reveal LINQ platform. Its AccuRhythm AI update was applied to Reveal LINQ devices in the U.S., Australia, and New Zealand in 2024, with the company reporting a projected 85% cumulative reduction in false atrial fibrillation and pause alerts. ^{[7]Medtronic, Medtronic Celebrates 10 Years of Reveal LINQ ICM by Adding Artificial Intelligence Algorithms, 2024, news.medtronic.com} The company's position is strongest where long monitoring duration and remote alert management are central to the clinical workflow.

Philips

Philips participates across ambulatory monitoring, in-hospital telemetry, ECG diagnostics, and clinical informatics. In 2025, the company introduced an ECG AI Marketplace intended to give care teams access to AI algorithm offerings in a centralized environment. Its collaboration with Epic to integrate ambulatory monitoring and diagnostic services into the Aura specialty diagnostics suite targets a persistent provider pain point: removing manual steps between test ordering, results review, and clinical documentation.

Boston Scientific Corporation

Boston Scientific's cardiac-monitoring portfolio includes the LUX-Dx insertable cardiac monitor family and the LATITUDE Clarity data-management platform. Its competitive role is concentrated in long-term implantable monitoring, where device detection algorithms and remote data-management capability determine the burden placed on electrophysiology and cardiology teams.

BIOTRONIK

BIOTRONIK introduced BIOMONITOR IV at the 2024 EHRA Congress after CE Mark approval. The company states that its SmartECG algorithm reduces false detections across major arrhythmia categories while retaining clinically relevant episodes. BIOTRONIK also partnered with the University of Sydney in 2025 to evaluate connected-health, remote-monitoring, and clinical-decision-support innovations through 2028, reinforcing its emphasis on integrating monitoring hardware with remote-care models.

Abbott Laboratories

Abbott's Assert-IQ insertable cardiac monitor received CE Mark in March 2024. The system combines AI-supported arrhythmia detection and Bluetooth connectivity; the Assert-IQ EL+ option is designed for more than six years of monitoring. Abbott's strategic position rests on addressing extended-surveillance indications while reducing the need for repeated in-clinic device interactions.

GE Healthcare

GE HealthCare serves the diagnostic ECG and clinical-monitoring market through its MAC and MUSE cardiology-information-system offerings. At ESC 2025, the company highlighted an integrated cardiology pathway and new AI-oriented innovations, including its ComboLab AltiX AI.i system. The company is differentiated by its installed hospital base and capacity to connect monitoring data with broader diagnostic and information-management workflows.

iRhythm Technologies

iRhythm's Zio platform is centered on extended-wear ambulatory ECG monitoring and analysis. The company received FDA 510(k) clearance in October 2024 for design updates previously made to its Zio AT device. Its Japan launch in 2025 expands the commercial footprint of its long-term continuous monitoring service and illustrates the company's focus on ambulatory, service-led cardiac monitoring.

AliveCor

AliveCor focuses on personal and handheld ECG technology. The June 2024 FDA clearances for Kardia 12L and KAI 12L AI extended its offering into a handheld 12-lead system with AI-enabled cardiac determinations. In May 2025, the company introduced KardiaMobile 6L Max and KardiaAlert, linking personal ECG capture with continuous-alert functionality. Its growth depends on converting accessible ECG acquisition into clinically usable workflows.

MicroPort

MicroPort presents cardiac rhythm management and electrophysiology solutions through MicroPort CRM. At EHRA 2025, the company showcased its CRM and EP portfolio, including diagnostic and monitoring capabilities. Its competitive opportunity lies in combining cardiac-rhythm products with established international sales and clinical-support channels.

BPL Medical

BPL Medical addresses Indian healthcare providers with cardiac and critical-care monitoring equipment. In December 2025, the company introduced new critical-care products at ISACON, including ExcelSign modular patient monitors and the Relife 1000 biphasic defibrillator. Its domestic-market position is supported by the need for accessible equipment suited to hospital and diagnostic-center procurement.

Schiller AG

Schiller specializes in cardiac diagnostic technologies, including Holter ECG systems. Its medilog portfolio supports extended ambulatory ECG recording and analysis, positioning the company in the segment where clinics require richer recordings than a basic short-term Holter study. The company's product orientation aligns with demand for longer-duration, multi-channel ambulatory diagnostics.

Recent Industry Developments

May 2025 - iRhythm Technologies launched the Zio ECG Recording and Analysis System in Japan. The company introduced its AI-powered long-term continuous ECG monitoring service in Japan through distributor Senko Medical Instrument.

May 2025 - AliveCor introduced KardiaMobile 6L Max and KardiaAlert. The launch combined a personal ECG device with an AI-powered alerting offering for continuous rhythm monitoring.

2025 - Philips announced an integration collaboration with Epic. The collaboration connects Philips ambulatory cardiac monitoring and diagnostics services with Epic's Aura specialty diagnostics suite.

2025 - Philips launched its ECG AI Marketplace. The marketplace provides a centralized environment for cardiac-care teams to access AI algorithms, with Anumana's ECG-AI Low Ejection Fraction algorithm as the initial offering.

2025 - BIOTRONIK and the University of Sydney entered a digital-cardiac-care collaboration. The parties agreed to develop and clinically evaluate connected-health, remote-monitoring, and decision-support innovations through 2028.

October 2024 - iRhythm received FDA 510(k) clearance for Zio AT design updates. The clearance covered design updates previously made to the ambulatory telemetry device.

June 2024 - AliveCor received FDA clearance for Kardia 12L and KAI 12L AI. The dual clearance supported the company's handheld AI-powered 12-lead ECG offering.

May 2024 - Medtronic expanded AccuRhythm AI across Reveal LINQ devices in selected markets. The cloud-based update targeted lower false-alert burden in insertable cardiac-monitoring workflows.